Public disclosure of inside information according to article 17 MAR
Heidelberg (pta016/30.12.2020/18:05) - The two members of the Management Board, Dr Heikki Lanckriet and Mr David Roth, and the Chairman of the Supervisory Board of the Company, Mr Joseph M. Fernández, today agreed that the two members of the Management Board, Dr Heikki Lanckriet and Mr David Roth, will each resign from the Management Board of 4basebio AG (formerly Expedeon AG) (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) with effect from today. Dr. Heikki Lanckriet and Mr. David Roth will focus on managing the operational business in the field of genomics and DNA manufacturing of 4basebio SE, whose spin-off from 4basebio AG and registration in the UK have already taken place. It is planned to admit the shares of 4basebio SE to trading on the Alternative Investment Market (AIM), a market segment of the London Stock Exchange, in January 2021.
The Supervisory Board would like to thank Dr Heikki Lanckriet and Mr David Roth for their many years of service to 4basebio AG. The remaining member of the Executive Board of 4basebio AG, Mr Hansjörg Plaggemars, will take over their areas of responsibility and will in future be responsible for the allocation of liquid funds to suitable investment opportunities within the biotech sector and in other areas.
*** end of ad hoc announcement ***
For further information, please contact:
T: + +49 151 5855 3113
Email: [email protected]
Dr. Robert Mayer
T: +49 171 3876540
Email: [email protected]
### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of 4basebio AG may deviate greatly from the established conclusions or implied predictions contained in such statements. 4basebio does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###